Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease

Andrea Caporali, Maryam Anwar, Yvan Devaux, Rajesh Katare, Fabio Martelli, Prashant Kumar Srivastava, Thierry Pedrazzini, Costanza Emanueli*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

The adult heart is a complex, multicellular organ that is subjected to a series of regulatory stimuli and circuits and has poor reparative potential. Despite progress in our understanding of disease mechanisms and in the quality of health care, ischaemic heart disease remains the leading cause of death globally, owing to adverse cardiac remodelling, leading to ischaemic cardiomyopathy and heart failure. Therapeutic targets are urgently required for the protection and repair of the ischaemic heart. Moreover, personalized clinical biomarkers are necessary for clinical diagnosis, medical management and to inform the individual response to treatment. Non-coding RNAs (ncRNAs) deeply influence cardiovascular functions and contribute to communication between cells in the cardiac microenvironment and between the heart and other organs. As such, ncRNAs are candidates for translation into clinical practice. However, ncRNA biology has not yet been completely deciphered, given that classes and modes of action have emerged only in the past 5 years. In this Review, we discuss the latest discoveries from basic research on ncRNAs and highlight both the clinical value and the challenges underscoring the translation of these molecules as biomarkers and therapeutic regulators of the processes contributing to the initiation, progression and potentially the prevention or resolution of ischaemic heart disease and heart failure.

Original languageEnglish
Pages (from-to)556-573
Number of pages18
JournalNature Reviews Cardiology
Volume21
Issue number8
Early online date18 Mar 2024
DOIs
Publication statusPublished - Aug 2024

Fingerprint

Dive into the research topics of 'Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease'. Together they form a unique fingerprint.

Cite this